The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict the company will post revenues of $10.95 billion, representing a 5% annual increase, when it announces the December-quarter results Friday before the opening bell.
Like many of its peers, Merck has been pushing its oncology portfolio aggressively with focus on Lynparza, Lenvima and Keytruda, which are considered to be among the most successful cancer therapies in the US. The popularity of Keytruda, especially after recent trials confirmed its effectiveness in treating multiple types of cancer, is expected to have a positive effect on the top-line performance this time. The other main business divisions, vaccines and animal health, also continue to be growth drivers.
Like many of its peers, Merck has been pushing its oncology portfolio aggressively with focus on Lynparza, Lenvima and Keytruda
In the next two years, the Kenilworth, New Jersey-based company will be expanding its production capacity, mainly in oncology and animal health, with an estimated investment of about $16 billion. It is expected that there will be an increase in R&D expenses in the fourth quarter, reflecting the management’s initiatives to revive research and development activities in the core areas of the business.
In the third quarter, the pharma giant’s revenues moved up 5% year-over-year to $10.8 billion but came in below expectations. Meanwhile, adjusted earnings climbed 7.2% to $1.19 per share, beating estimates. Revenues from the vaccine business grew 13% mainly due to the growing demand for Gardasil in the overseas market.
Currently, the average analysts’ rating on Merck is buy. The positive recommendation and the increased price target of $81 make the stock an investment option worth considering.
Among Merck’s peers, Eli Lilly (LLY) is scheduled to release its fourth quarter results on February 13 before the market opens. Last week, AbbVie (ABBV) reported weaker than expected earnings for the most recent quarter – despite a marked increase in revenues – hurt mainly by acquisition-related charges.
Merck’s stock climbed to a seven-year high last month, after rising steadily throughout 2018. The stock, which gained about 25% in the past twelve months, traded slightly lower during Wednesday’s regular session.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,